Inhaled mealtime insulin with the AERxA iDMS versus subcutaneous injected insulin aspart both in combination with insulin detemir in type 1 diabetes: a 104 week, open-label, multicenter, randomised, parallel trial (followed by a twelve-week re-randomised extension) to investigate safety and efficacy.

Trial Profile

Inhaled mealtime insulin with the AERxA iDMS versus subcutaneous injected insulin aspart both in combination with insulin detemir in type 1 diabetes: a 104 week, open-label, multicenter, randomised, parallel trial (followed by a twelve-week re-randomised extension) to investigate safety and efficacy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Insulin (Primary) ; Insulin aspart; Insulin detemir
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jan 2008 Status changed from in progress to discontinued as reported by ClinicalTrials.gov.
    • 12 Jun 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top